Co-Founder and CEO Alex Aravanis describes how epigenentic engineering could have advantages over gene editing.

Stéphane Bancel talks about Moderna's programs for COVID, RSV, CMV, cancer, and more.

Robert Blum describes Aficamten’s topline safety, efficacy, and how the company views its competitive profile.

Co-Founder & CEO Ashley Zehnder describes how Fauna studies animals that have disease resistance to help tackle human disease.

Thomas Butler describes Biomea's hypothesis of utilizing a covalent, irreversible menin inhibitor to promote beta cell proliferation.

Apple Tree Partner and Deep Apple CEO Spiros Liras describes how the company aims to leverage virtual screening and machine learning.

Celine Halioua describes how Loyal is trying to extend the lifespan of dogs, and explains recent FDA feedback.

Syndax's CEO reviews late breaking data on the menin inhibitor revumenib in KMT2A-rearranged leukemias and discusses axatilimab's GvHD data.

Brian Goff highlights data from the phase 2 portion of the RISE UP pivotal study of Mitapivat for SCD that was presented at #ASH23 today.

William Cao describes how the same product might be used for cancer and lupus, and explains the idea behind FasTCAR manufacturing.

Arthur Sands elaborates on two programs Nurix presented updated data for at ASH and dives into the company's pipeline and partnerships.

Kristin Yarema describes how she believes that honing in on the right preconditioning regimen might be a success factor.

Stuart Arbuckle describes the approval and launch dynamics of this gene-edited cell therapy.

Hervé Hoppenot discusses Incyte's #ASH23 presentations, the company's pipeline, success in dermatology, and how he thinks about Jakafi.

Dinesh Patel describes the science behind Protagonist's polycythemia vera program and oral IL23.

Rami Elghandour compares Arcellx's estimated 28 month PFS to Carvykti and gives his take on the recent FDA notice about CAR-T.

Michael Henderson describes the rationale behind Apogee's IL13 program and how it has been designed to have a longer half-life.

Vir's new CEO gives an overview of the company's programs and discusses future plans to expand into autoimmune disease and oncology.

Amit Etkin says that psychiatric conditions have been treated too broadly in the past.

Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 in ADH1 and investing in early science.